Dax Wolford, MD
Psychiatry · Las Vegas, NVNPI 1851742100
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 84.4% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $25,457, more than ten times the $83 reported in 2022. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $111.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25K
- AbbVie$1K
- Alkermes, Inc.$627
- E.r. Squibb & Sons, L.L.C.$623
- Neurocrine Biosciences, Inc.$418
- Axsome Therapeutics, Inc.$280
- plus $1K from 13 others
What the payments were for
- Consulting fees$2,97010%
- Speaking & faculty fees$17,28059%
- Travel & lodging$2,87710%
- Food & beverage$6,01821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 102 | $24,606 |
| AbbVie | 45 | $1,381 |
| Alkermes, Inc. | 18 | $627 |
| E.r. Squibb & Sons, L.L.C. | 19 | $623 |
| Neurocrine Biosciences, Inc. | 12 | $418 |
| Axsome Therapeutics, Inc. | 11 | $280 |
| Idorsia Pharmaceuticals US Inc | 9 | $247 |
| Johnson & Johnson | 5 | $193 |
| Almatica Pharma LLC | 10 | $151 |
| Otsuka America Pharmaceutical, Inc. | 6 | $132 |
| Teva Pharmaceuticals USA, Inc. | 6 | $103 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Lundbeck LLC | 4 | $80 |
| Bausch Health US, LLC | 3 | $60 |
| Tris Pharma Inc | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 1 | $29 |
| Sage Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,145 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SavellaMilnacipran Hcl | 17 | $7,259 |
| DayvigoLemborexant | 11 | $3,649 |
| Duloxetine Hcl | 69 | $1,046 |
| Bupropion XlBupropion Hcl | 39 | $1,027 |
| Doxepin Hcl | 11 | $859 |
| Amitriptyline Hcl | 73 | $836 |
| Aripiprazole | 17 | $809 |
| Mirtazapine | 43 | $537 |
| Naltrexone Hcl | 12 | $504 |
| Bupropion Hcl | 18 | $413 |
| Buspirone Hcl | 44 | $407 |
| Quetiapine Fumarate | 39 | $393 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $274 |
| Olanzapine | 29 | $256 |
| Trazodone Hcl | 63 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSavella | $1,381 | $7,25917 claims |
| Almatica Pharma LLCSertraline Hcl | $151 | $11327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
- John VallesLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.